ReviewJournal of gastrointestinal cancer2026
Tools and Techniques of Endoscopic Radiofrequency Ablation in Pancreaticobiliary Diseases: A Narrative Review.
Review in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndoscopic radiofrequency ablation (RFA) has become an established minimally invasive option for patients with pancreaticobiliary tumors who are not candidates for resection or who have obstructing lesions of the bile duct or pancreas. This narrative review summarizes the devices, technique, and supporting clinical evidence for endoscopic RFA, organized by clinical indication rather than by device alone.
objectiveRFA delivers high-frequency alternating current that produces localized thermal injury and coagulative necrosis. Two endoscopic delivery routes are in use: an ERCP-guided approach, which treats intraductal lesions such as malignant biliary strictures and ampullary tumors using bipolar endobiliary catheters, and an EUS-guided approach, which uses a monopolar needle electrode to ablate pancreatic parenchymal lesions, including solid tumors, neuroendocrine tumors, and pancreatic cysts and intraductal papillary mucinous neoplasms (IPMN). Hybrid needles that combine fine-needle aspiration with ablation are an emerging, still investigational, third category. SYNTHESIS/
resultsAcross the published series, technical success generally exceeds 90% for both approaches, with adverse event rates that are mostly low and dominated by self-limited abdominal pain, mild pancreatitis, or cholangitis; perforation and clinically significant bleeding are uncommon when established energy and safety-margin parameters are followed. A proposed, but still poorly characterized, immune-stimulating effect of ablation-induced tissue injury is discussed as a hypothesis rather than an established mechanism.
conclusionsTaken together, the available data support endoscopic RFA as a useful adjunct in the multidisciplinary management of pancreaticobiliary disease, but most of the supporting literature consists of small, single-arm, or retrospective series. Prospective, ideally randomized, studies with standardized energy protocols and longer follow-up are needed before the technique's role in routine practice, particularly for pancreatic cystic lesions and IPMN, can be considered settled.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.